Jeff Roix

Jeff Roix has extensive experience in the biotechnology and pharmaceutical sectors, currently serving as Interim CEO at Stingray Bio Ltd and Director at Opal Therapeutics, both since March 2021, while also holding the position of Venture Partner at o2h ventures since July 2020. Previously, Jeff Roix led NeoPhore Ltd as CEO, focusing on novel small molecule immuno-oncology therapeutics, and served as COO at PhoreMost Ltd, which specializes in developing small-molecule drugs using proprietary technology. Early career roles include positions at BioMed Valley Discoveries, Constellation Pharmaceuticals, Novartis, and a technician role at MIT. Jeff Roix holds an ALB in Biology from Harvard University, obtained between 2002 and 2009.